Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
This is a Phase II, open-label study designed to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of AL01211 in male subjects with classic Fabry disease who have never received any treatment (eg. ERT or chaperone therapy). Eligible subjects will receive 182 days (26 weeks) of study treatment as the primary study period followed by an extension period. The total study duration for a subject is up to at most 2 years including the primary period of 26 weeks.
Epistemonikos ID: 9d9da62c39322249fd0641b3668f32495b5f63bc
First added on: May 15, 2024